Last updated: July 28, 2026
Mannitol 10% is a longstanding, widely stocked intravenous osmotic agent used for indications including increased intracranial pressure, cerebral edema adjunct therapy, and lowering intraocular pressure. Clinical development activity for “mannitol 10%” products is largely incremental and product-line driven rather than originator-class innovation. Forecasting is therefore dominated by (1) hospital demand for IV osmotic therapy, (2) substitution across concentrations and brands (often with equivalent-osmolarity use), (3) supply continuity and pricing, and (4) regulatory and litigation risk around generic entries rather than new-entity clinical endpoints.
What clinical trials are ongoing or recently completed for mannitol 10% (IV mannitol injection)?
No complete, drug-label-specific public dataset is available in the provided information to enumerate ongoing or recently completed clinical trials for the exact product “mannitol 10%” (as opposed to “mannitol” across concentrations). A reliable, citation-backed update requires trial registries (e.g., ClinicalTrials.gov EU CTR) with product form and concentration fields mapped to “mannitol 10%” entries. Without that, a complete and accurate trials table cannot be produced.
Are there new randomized trials for mannitol to treat cerebral edema or intracranial pressure?
For osmotherapy, clinical literature commonly evaluates mannitol use within broader neurocritical care contexts, but these trials typically target “mannitol” generically or include concentration/infusion protocols without tracking “10% injection” as a standalone investigational product. Product-specific clinical readouts for “mannitol 10%” are not routinely separable into a standalone development program.
Does mannitol 10% have any recent Phase 3 program?
Mannitol is an established active ingredient with mature manufacturing and generic competition. Phase 3 programs specifically for “mannitol 10%” are uncommon in public filings, and when studies exist, they often relate to formulation, administration practices, or comparative effectiveness rather than licensing a new active ingredient.
When does mannitol 10% lose exclusivity and what does that mean for generic entry timing?
A complete exclusivity and patent-expiration analysis for “mannitol 10%” cannot be generated from the provided information. Mannitol is a mature, off-patent ingredient in most markets, and “product exclusivity” varies by jurisdiction and by whether the reference product is a brand formulation with separate regulatory exclusivities. A correct, decision-grade timeline requires Orange Book or equivalent listing data for specific reference products labeled as “mannitol 10% injection.”
What patents protect mannitol 10% (formulation, method-of-use, and manufacturing)?
No patent estate can be compiled for “mannitol 10%” without identifying a reference listed drug (RLD) and specific NDA/BLA numbers or Orange Book identifiers tied to “mannitol 10%.” For mannitol, patents (where they exist) are typically concentrated in process improvements, container/closure systems, or niche formulation claims rather than the active ingredient itself.
How many patents cover mannitol 10% and who holds them?
Cannot be enumerated without RLD-level data (NDA holder, patent numbers, claims, expiration dates) tied to “mannitol 10%.”
Which method-of-use patents exist for osmotic therapy with mannitol?
Cannot be reliably mapped without the jurisdiction and specific patent family list. Method-of-use patents for intracranial pressure and edema are often broad and may not be enforceable against standard generic osmotherapy regimens.
What is the Orange Book status of mannitol 10% in the US?
Orange Book status is product-specific. “Mannitol 10%” can map to multiple listed products depending on concentration, dosage form, package size, and manufacturer. A correct status requires the RLD name and NDA number(s) to check listing types (drug substance/active ingredient, drug product, patents) and expiration dates.
What formulations are protected by mannitol 10% patents or product IP?
Without the underlying patent listing and RLD mapping, formulation-specific coverage cannot be stated. In practice, concentration variants (e.g., 10%, 20%) can be treated as distinct SKUs for supply and procurement, even if clinically interchangeable.
How strong is the patent estate for mannitol 10% and what is the litigation risk?
No litigation-risk profile can be generated without: (1) patent list, (2) Paragraph IV filings (if any) tied to the relevant RLD, and (3) docket histories for generic entrants.
What generic entry risks exist for mannitol 10%?
Mannitol’s active ingredient is mature, and generic substitution is generally the norm in hospital procurement. The main competitive risks for a specific “mannitol 10%” product are supply chain continuity, container integrity, and pricing pressure rather than patent barriers. A precise entry-risk map still requires RLD-level exclusivity and approved-abbreviated pathway status.
How does mannitol 10% compare with mannitol 20% and other osmotic agents (hypertonic saline) in market access?
Competitive dynamics for IV osmotherapy are shaped by:
- Clinical protocol preference (ICU pathways often allow either mannitol or hypertonic saline depending on institutional guidelines).
- Osmolality and dosing logistics (10% versus 20% changes infusion rates and volume burden).
- Formulary rules and procurement contracts.
- Safety monitoring and administration requirements.
A quantified comparative market-access analysis requires sales and contracting data that is not included.
Market analysis for mannitol 10%: demand drivers, pricing, and competitive landscape
Core demand drivers (hospital and critical care)
Mannitol 10% demand is driven by:
- Neurocritical care volumes (trauma, stroke, intracranial pathology).
- Perioperative and ophthalmic pathways when mannitol is used to manage intraocular pressure adjunctively.
- Emergency department throughput and ICU admission rates.
- Treatment protocol adherence and stock coverage requirements.
Competitive landscape (typical structure)
The market for mannitol injection is usually characterized by:
- Multiple ANDA-approved generic manufacturers across concentrations and package sizes.
- Occasional manufacturer-specific supply disruptions that impact availability and pricing.
- Procurement contracting that favors low-cost, dependable supply.
Pricing and margin dynamics
Generic IV products typically experience:
- Rapid downward pricing after broad generic availability.
- Margin compression during supply normalization.
- Contract-based pricing with limited ability to raise price absent shortages.
A precise pricing range and margin outlook cannot be computed without unit sales, ASP, and procurement data.
Market projection and revenue forecast for mannitol 10% (base, upside, downside scenarios)
A revenue projection requires at least one of the following: historical global or US sales of mannitol injection by concentration, hospital purchasing data, or manufacturer revenue attribution. None is provided.
Given the inability to source or compute credible baseline volumes and pricing, any quantified forecast would be incomplete and not decision-grade.
Key Takeaways
- “Mannitol 10%” clinical development is not typically anchored to a standalone product innovation pipeline; most change is incremental and supply or practice driven.
- A precise clinical trials update (ongoing and completed) for the exact “mannitol 10%” concentration cannot be produced from the information provided.
- Exclusivity, Orange Book status, and patent/litigation timelines require RLD/NDA-level product mapping and listed patent datasets.
- Market outlook is dominated by hospital demand for IV osmotherapy and generic substitution, with pricing and availability more important than patent leverage.
- A quantified revenue projection cannot be generated without historical sales and market sizing inputs tied to “mannitol 10% injection.”
FAQs
- Is mannitol 10% interchangeable with mannitol 20% clinically in ICU protocols?
- What is the typical US procurement behavior for generic IV mannitol injections during supply disruptions?
- Do biosimilar or biologics pathways apply to mannitol 10%?
- How do container sizes (e.g., 100 mL vs 250 mL) affect hospital formulary selection for mannitol 10%?
- What non-patent barriers most often impact market entry for sterile IV generic injections like mannitol 10%?
References (APA)
No sources were provided or can be cited based on the information available in the prompt.
